MCID: CTS001
MIFTS: 59

Cutis Laxa malady

Categories: Genetic diseases, Rare diseases, Skin diseases, Neuronal diseases, Eye diseases, Metabolic diseases, Fetal diseases, Mental diseases, Bone diseases, Gastrointestinal diseases, Nephrological diseases, Cardiovascular diseases

Aliases & Classifications for Cutis Laxa

About this section

Summaries for Cutis Laxa

About this section
NIH Rare Diseases:48 Cutis laxa is a connective tissue disorder characterized by skin that is sagging and not stretchy. The skin often hangs in loose folds, causing the face and other parts of the body to have a droopy appearance. Cutis laxa can also affect connective tissue in other parts of the body, including the heart, blood vessels, joints, intestines, and lungs. Depending on which organs and tissues are affected, the signs and symptoms can range from mild to life-threatening. It may be acquired or inherited. The different forms of inherited cutis laxa are distinguished by their pattern of inheritance: autosomal dominant, autosomal recessive, or X-linked. In general, the autosomal recessive forms tend to be more severe than the autosomal dominant form. The X-linked form of cutis laxa is often called occipital horn syndrome. Last updated: 4/1/2016

MalaCards based summary: Cutis Laxa, also known as generalized elastolysis, is related to cutis laxa, autosomal dominant 2 and cutis laxa, ad, and has symptoms including cutis laxa, patent ductus arteriosus and hernia of the abdominal wall. An important gene associated with Cutis Laxa is FBLN5 (Fibulin 5), and among its related pathways are Arginine and proline metabolism and Amino acid synthesis and interconversion (transamination). Affiliated tissues include skin, heart and lung, and related mouse phenotypes are integument and muscle.

Disease Ontology:11 A skin disease characterized by skin that is loose, hanging, wrinkled and lacking in elasticity; it can also affect connective tissue in other parts of the body, including the heart, blood vessels, joints, intestines and lungs.

Genetics Home Reference:25 Cutis laxa is a disorder of connective tissue, which is the tissue that forms the body's supportive framework. Connective tissue provides structure and strength to the muscles, joints, organs, and skin.

Wikipedia:71 Cutis laxa (also known as Chalazoderma, Dermatochalasia, Dermatolysis, Dermatomegaly, Generalized... more...

Related Diseases for Cutis Laxa

About this section

Diseases in the Cutis Laxa family:

Cutis Laxa, Ad Cutis Laxa, Autosomal Recessive, Type Iiia
Cutis Laxa, Autosomal Dominant 3 Cutis Laxa, Autosomal Recessive, Type Ib
Cutis Laxa, Autosomal Recessive, Type Iia Cutis Laxa, Autosomal Recessive, Type Ia
Cutis Laxa, Autosomal Dominant 2 Cutis Laxa, Autosomal Recessive, Type Iib
Cutis Laxa, Autosomal Recessive, Type Iiib Cutis Laxa, Autosomal Recessive, Type Ic
Atp6v0a2-Related Cutis Laxa Efemp2-Related Cutis Laxa
Fbln5-Related Cutis Laxa Ltbp4-Related Cutis Laxa
Cutis Laxa, Autosomal Dominant Cutis Laxa, Autosomal Recessive Type 1
Aldh18a1-Related Cutis Laxa Eln-Related Cutis Laxa
Pycr1-Related Cutis Laxa Acquired Cutis Laxa

Diseases related to Cutis Laxa via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 138)
idRelated DiseaseScoreTop Affiliating Genes
1cutis laxa, autosomal dominant 234.2EFEMP2, FBLN5
2cutis laxa, ad33.1ELN, FBLN5, FBN1
3cutis laxa, autosomal recessive, type iia12.5
4cutis laxa, autosomal recessive, type ia12.4
5cutis laxa, autosomal recessive, type iib12.4
6cutis laxa, autosomal recessive, type ic12.4
7cutis laxa, autosomal recessive, type iiib12.4
8cutis laxa, autosomal recessive, type iiia12.4
9cutis laxa, autosomal recessive, type ib12.4
10cutis laxa, autosomal dominant 312.3
11atp6v0a2-related cutis laxa12.3
12macrocephaly, alopecia, cutis laxa, and scoliosis12.2
13efemp2-related cutis laxa12.2
14cutis laxa, autosomal dominant12.2
15acquired cutis laxa12.2
16ltbp4-related cutis laxa12.1
17cutis laxa, autosomal recessive type 112.1
18fbln5-related cutis laxa12.1
19aldh18a1-related cutis laxa12.1
20pycr1-related cutis laxa12.0
21cutis laxa, neonatal, with marfanoid phenotype12.0
22dysmorphism cleft palate loose skin12.0
23cutis laxa osteoporosis11.9
24eln-related cutis laxa11.9
25occipital horn syndrome11.8
26de barsy syndrome11.5
27wrinkly skin syndrome11.3
28menkes disease11.3
29scarf syndrome11.3
30ehlers-danlos syndrome, type viic11.0
31transaldolase deficiency11.0
32cantu sanchez-corona hernandez syndrome10.9
33lenz-majewski hyperostotic dwarfism10.7
34trichorhinophalangeal syndrome, type ii10.7
35cutis verticis gyrata mental deficiency10.5EFEMP2, FBLN5
36esophagitis, eosinophilic, 110.4ELN, FBLN5
37late-onset focal dermal elastosis10.4ELN, FBLN5
38flna-related periventricular nodular heterotopia10.4ELN, FBLN5
39chronic ethmoiditis10.4EFEMP2, FBLN5
40multiple myeloma10.3
41angiosarcoma10.3ALDH18A1, ELN
42pseudoxanthoma elasticum10.2
43amyloidosis10.2
44du pan syndrome10.2FBLN5, RIN2
45pulmonary emphysema10.1
46ehlers-danlos syndrome10.1
47spastic paraplegia 110.1ALDH18A1, ELN, FBLN5
48anoxia10.1EFEMP2, ELN, FBLN5
49costello syndrome10.1
50elastosis perforans serpiginosa10.1

Graphical network of the top 20 diseases related to Cutis Laxa:



Diseases related to cutis laxa

Symptoms & Phenotypes for Cutis Laxa

About this section

Human phenotypes related to Cutis Laxa:

 64 (show all 65)
id Description HPO Frequency HPO Source Accession
1 cutis laxa64 hallmark (90%) HP:0000973
2 patent ductus arteriosus64 hallmark (90%) HP:0001643
3 hernia of the abdominal wall64 hallmark (90%) HP:0004299
4 short stature64 hallmark (90%) HP:0004322
5 bowel diverticulosis64 hallmark (90%) HP:0005222
6 prematurely aged appearance64 hallmark (90%) HP:0007495
7 abnormality of retinal pigmentation64 hallmark (90%) HP:0007703
8 aplasia/hypoplasia of the abdominal wall musculature64 hallmark (90%) HP:0010318
9 esophageal diverticulum64 hallmark (90%) HP:0100628
10 lack of skin elasticity64 hallmark (90%) HP:0100679
11 recurrent urinary tract infections64 typical (50%) HP:0000010
12 vesicoureteral reflux64 typical (50%) HP:0000076
13 narrow mouth64 typical (50%) HP:0000160
14 abnormality of the palate64 typical (50%) HP:0000174
15 hydrocephalus64 typical (50%) HP:0000238
16 epicanthus64 typical (50%) HP:0000286
17 long philtrum64 typical (50%) HP:0000343
18 micrognathia64 typical (50%) HP:0000347
19 low-set, posteriorly rotated ears64 typical (50%) HP:0000368
20 depressed nasal ridge64 typical (50%) HP:0000457
21 thickened nuchal skin fold64 typical (50%) HP:0000474
22 telecanthus64 typical (50%) HP:0000506
23 ptosis64 typical (50%) HP:0000508
24 carious teeth64 typical (50%) HP:0000670
25 pectus excavatum64 typical (50%) HP:0000767
26 muscular hypotonia64 typical (50%) HP:0001252
27 muscle weakness64 typical (50%) HP:0001324
28 plagiocephaly64 typical (50%) HP:0001357
29 joint dislocation64 typical (50%) HP:0001373
30 intrauterine growth retardation64 typical (50%) HP:0001511
31 frontal bossing64 typical (50%) HP:0002007
32 malabsorption64 typical (50%) HP:0002024
33 abnormality of the bronchi64 typical (50%) HP:0002109
34 recurrent respiratory infections64 typical (50%) HP:0002205
35 bowel incontinence64 typical (50%) HP:0002607
36 scoliosis64 typical (50%) HP:0002650
37 short nose64 typical (50%) HP:0003196
38 abnormality of the hip bone64 typical (50%) HP:0003272
39 ectopic anus64 typical (50%) HP:0004397
40 aplasia/hypoplasia of the tongue64 typical (50%) HP:0010295
41 cognitive impairment64 typical (50%) HP:0100543
42 genital hernia64 typical (50%) HP:0100823
43 malar flattening64 occasional (7.5%) HP:0000272
44 hypertelorism64 occasional (7.5%) HP:0000316
45 anteverted nares64 occasional (7.5%) HP:0000463
46 short neck64 occasional (7.5%) HP:0000470
47 downslanted palpebral fissures64 occasional (7.5%) HP:0000494
48 pectus carinatum64 occasional (7.5%) HP:0000768
49 hypothyroidism64 occasional (7.5%) HP:0000821
50 eczema64 occasional (7.5%) HP:0000964
51 urticaria64 occasional (7.5%) HP:0001025
52 macular coloboma64 occasional (7.5%) HP:0001116
53 seizures64 occasional (7.5%) HP:0001250
54 craniosynostosis64 occasional (7.5%) HP:0001363
55 ventricular septal defect64 occasional (7.5%) HP:0001629
56 atria septal defect64 occasional (7.5%) HP:0001631
57 congestive heart failure64 occasional (7.5%) HP:0001635
58 abnormality of the heart valves64 occasional (7.5%) HP:0001654
59 abnormality of metabolism/homeostasis64 occasional (7.5%) HP:0001939
60 leukocytosis64 occasional (7.5%) HP:0001974
61 respiratory insufficiency64 occasional (7.5%) HP:0002093
62 emphysema64 occasional (7.5%) HP:0002097
63 decreased body weight64 occasional (7.5%) HP:0004325
64 abnormal blistering of the skin64 occasional (7.5%) HP:0008066
65 exostoses64 occasional (7.5%) HP:0100777

UMLS symptoms related to Cutis Laxa:


pruritus

MGI Mouse Phenotypes related to Cutis Laxa according to GeneCards Suite gene sharing:

41
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00107718.7EFEMP2, FBLN5, FBN1, LOX, LTBP4
2MP:00053698.7EFEMP2, FBLN5, FBN1, LOX, LTBP4
3MP:00053888.0EFEMP2, FBLN5, FBN1, LOX, LTBP4

Drugs & Therapeutics for Cutis Laxa

About this section

Drugs for Cutis Laxa (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 73)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Lidocaineapproved, vet_approvedPhase 4, Phase 31226137-58-63676
Synonyms:
.alpha.-(Diethylamino)-2,6-acetoxylidide
.alpha.-Diethylamino-2,6-dimethylacetanilide
.alpha.-Diethylaminoaceto-2,6-xylidide
.omega.-Diethylamino-2,6-dimethylacetanilide
137-58-6
2-(Diethylamino)-2',6'-acetoxylidide
2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamide
2-Diethylamino-N-(2,6-dimethyl-phenyl)-acetamide
2-Diethylamino-N-(2,6-dimethylphenyl)acetamide
4-12-00-02538 (Beilstein Handbook Reference)
6108-05-0 (MONOHYDROCHLORIDE MONOHYDRATE))
6108-05-0 (mono-hydrochloride, mono-hydrate)
73-78-9 (mono-hydrochloride)
AB00053581
AC-10282
AC1L1GGQ
AC1Q2Z7J
AKOS001026768
ARONIS23855
After Burn Double Strength Gel
After Burn Double Strength Spray
After Burn Gel
After Burn Spray
Alphacaine
Anestacon
Anestacon Jelly
BIDD:GT0342
BPBio1_000197
BRD-K52662033-001-02-6
BRD-K52662033-003-05-5
BRN 2215784
BSPBio_000179
BSPBio_001359
BSPBio_003004
Bio-0767
Bio1_000379
Bio1_000868
Bio1_001357
Bio2_000079
Bio2_000559
C07073
C14H22N2O
CAS-73-78-9
CDS1_000283
CHEBI:6456
CHEMBL79
CID3676
CPD000058189
Cappicaine
Cito optadren
Cuivasil
D00358
DB00281
Dalcaine
Dentipatch
Dentipatch (TN)
DermaFlex
Diethylaminoaceto-2,6-xylidide
Dilocaine
DivK1c_000174
DivK1c_001323
Duncaine
EINECS 205-302-8
ELA-Max
EMBOLEX
Emla
Emla Cream
Esracaine
FT-0082378
Gravocain
HMS1791D21
HMS1989D21
HMS2051C21
HMS2089E15
HMS548M19
HSDB 3350
I01-2704
IDI1_000174
IDI1_033829
Isicaina
Isicaine
Jetocaine
KBio1_000174
KBio2_000079
KBio2_001598
KBio2_002647
KBio2_004166
KBio2_005215
KBio2_006734
KBio3_000157
KBio3_000158
KBio3_002224
KBioGR_000079
KBioGR_000599
KBioSS_000079
KBioSS_001598
L-Caine
L0156
L1026_SIGMA
L7757_SIGMA
LIDOCAINE (73-58-6 (MONOHYDROCHLORIDE)
LIDOPEN
LQZ
 
LS-805
Lanabiotic
Leostesin
Lida-Mantle
Lidocaina
Lidocaina [INN-Spanish]
Lidocaine (JP15/USP/INN)
Lidocaine (VAN)
Lidocaine Carbonate
Lidocaine Hydrocarbonate
Lidocaine Monohydrochloride
Lidocaine [USAN:INN:JAN]
Lidocainum
Lidocainum [INN-Latin]
Lidocaton
Lidoderm
Lidoject-1
Lidoject-2
Lignocaine
Lignocainum
Lingocaine
Lopac-L-5647
Lopac0_000669
MLS000069724
MLS000758263
MLS001074177
Maricaine
Maybridge1_002571
MolPort-001-783-478
N-(2,6-dimethylphenyl)-N(2),N(2)-diethylglycinamide
N-(2,6-dimethylphenyl)-N~2~,N~2~-diethylglycinamide
NCGC00015611-01
NCGC00015611-02
NCGC00015611-03
NCGC00015611-04
NCGC00015611-14
NCGC00022176-05
NCGC00022176-06
NCGC00022176-07
NCGC00022176-08
NCGC00022176-09
NINDS_000174
NSC 40030
NSC40030
Norwood Sunburn Spray
Octocaine
Octocaine-100
Octocaine-50
Prestwick0_000050
Prestwick1_000050
Prestwick2_000050
Prestwick3_000050
Remicaine
Rocephin Kit
Rucaina
S1357_Selleck
SAM001247018
SMR000058189
SPBio_001525
SPBio_002100
STK552033
Solarcaine
Solarcaine aloe extra burn relief cream
Solcain
Spectrum2_001343
Spectrum3_001392
Spectrum4_000070
Spectrum5_001549
Spectrum_001118
UNII-98PI200987
WLN: 2N2 & 1VMR B1 F1
Xilina
Xilocaina
Xilocaina [Italian]
Xllina
Xycaine
Xylestesin
Xylesthesin
Xylocain
Xylocaine
Xylocaine (TN)
Xylocaine 5% Spinal
Xylocaine CO2
Xylocaine Dental Ointment
Xylocaine Endotracheal
Xylocaine Test Dose
Xylocaine Viscous
Xylocaine-MPF
Xylocaine-MPF with Glucose
Xylocaine-Mpf
Xylocaine-Mpf with Glucose
Xylocard
Xylocitin
Xyloneural (free base)
Xylotox
Zilactin-L
Zingo
alfa-Dietilamino-2,6-dimetilacetanilide
alfa-Dietilamino-2,6-dimetilacetanilide [Italian]
alpha-Diethylamino-2,6-dimethylacetanilide
alpha-diethylamino-2,6-dimethylacetanilide
lidocaine
nchembio.65-comp16
α-diethylamino-2,6-dimethylacetanilide
2
Epinephrineapproved, vet_approvedPhase 4, Phase 393351-43-45816
Synonyms:
(-)-(R)-Epinephrine
(-)-3,4-Dihydroxy-a-[2-(methylamino)ethyl]benzyl alcohol
(-)-3,4-Dihydroxy-alpha-((methylamino)methyl)benzyl alcohol
(-)-3,4-Dihydroxy-alpha-[2-(methylamino)ethyl]benzyl alcohol
(-)-3,4-dihydroxy-a-[(methylamino)methyl]-Benzyl alcohol
(-)-3,4-dihydroxy-alpha-[(methylamino)methyl]-Benzyl alcohol
(-)-Adrenalin
(-)-Adrenaline
(-)-Epinephrine
(-)-R-Epinephrine
(R)-(-)-Adnephrine
(R)-(-)-Adrenaline
(R)-(-)-Epinephrine
(R)-(-)-Epirenamine
(R)-(−)-adrenaline
(R)-4-[1-Hydroxy-2-(methylamino)ethyl]-1,2-benzenediol
(R)-4-[1-hydroxy-2-(methylamino)ethyl]-1,2-Benzenediol
(R)-Adrenaline
(R)-Epinephrine
(−)-adrenaline
02252_FLUKA
1-1-(3,4-Dihydroxyphenyl)-2-methylaminoethanol
1-Adrenalin
1-Epinephrine
4-(1-Hydroxy-2-(methylamino)ethyl)-1,2-benzenediol
4-(1-hydroxy-2-methylamino-ethyl)benzene-1,2-diol
4-[(1R)-1-Hydroxy-2-(methylamino)ethyl]-1,2-Benzenediol
4-[(1R)-1-Hydroxy-2-(methylamino)ethyl]-1,2-benzenediol
4-[(1R)-1-hydroxy-2-(methylamino)ethyl]benzene-1,2-diol
51-43-4
51-43-4 (FREE BASE)
51028-73-0
A0173
AC-13188
AC1L1L7B
ADR ADRENALINE
ADROP
AI3-19015
Adnephrine
Adrenal
Adrenalin
Adrenalin (TN)
Adrenalin in Oil
Adrenalin-Medihaler
Adrenalina
Adrenalina [DCIT]
Adrenaline
Adrenaline (JP15)
Adrenaline/Epinephrine
Adrenalinum
Adrenamine
Adrenan
Adrenapax
Adrenasol
Adrenatrate
Adrenine
Adrenodis
Adrenohorma
Adrenosan
Adrenutol
Adrin
Adrine
Ana-Guard
Ana-Kit
Antiasthmatique
Asmatane Mist
Asthma meter mist
Asthma-nefrin
Asthmahaler Mist
Asthmanefrin
Astmahalin
Astminhal
BIDD:GT0119
Balmadren
Bernarenin
Biorenine
Bosmin
Brevirenin
Bronkaid
Bronkaid Mist
Bronkaid Suspension Mist
Bupivacaine Hcl and Epinephrine
C00788
CCRIS 4812
CHEBI:28918
CHEMBL679
CID5816
Chelafrin
Citanest Forte
Corisol
D-Epifrin
D-Epinephrine
D00095
DB00668
Drenamist
Dylephrin
Dyspne-Inhal
E4250_SIGMA
EINECS 200-098-7
EPI E Z PEN JR
EPIPEN E Z PEN
EPIPEN JR
Epi EZ Pen Jr
Epifrin
Epiglaufrin
Epinefrin
Epinefrin [Czech]
Epinefrina
Epinefrina [INN-Spanish]
Epinephran
Epinephrin
Epinephrine
Epinephrine (USP)
Epinephrine (USP/INN)
Epinephrine [USAN:INN:JAN]
Epinephrine hydrochloride
Epinephrinum
Epinephrinum [INN-Latin]
Epipen
Epipen (TN)
Epipen Auto-Injector
Epipen EZ Pen
Epipen Jr.
Epipen Jr. Auto-Injector
Epirenamine
Epirenan
Epirenin
Epitrate
Eppy
Esphygmogenina
Exadrin
 
Glaucon
Glaucosan
Glauposine
Glycirenan
HSCI1_000215
HSDB 4289
Haemostasin
Haemostatin
Hektalin
Hemisine
Hemostasin
Hemostatin
Hypernephrin
Hyporenin
IOP
Intranefrin
Iontocaine
Isoptoepinal
Kidoline
L-1-(3,4-Dihydroxyphenyl)-2-methylaminoethanol
L-Adrenaline
L-Adrenaline Base
L-Epinehphrine
L-Epinephrine
L-Epirenamine
L-Methylaminoethanolcatechol
L-epinephrine
LS-156
Levo-Methylaminoethanolcatechol
Levoadrenaline
Levoepinephrine
Levorenen
Levorenin
Levorenine
Levoreninum
Lopac-E-4642
Lyodrin
Lyophrin
Medihaler-Epi
Metanephrin
Methylaminoethanolcatechol
Methylarterenol
Micronefrin
Micronephrine
MolPort-002-051-368
Mucidrina
Myosthenine
Mytrate
NCGC00015417-01
NCGC00142615-01
NCGC00142615-03
NCGC00142615-04
NCGC00142615-05
NCGC00142615-06
NCGC00142615-07
NSC 62786
NSC62786
Nephridine
Nieraline
PDSP1_001120
PDSP2_001104
Paranephrin
Primatene
Primatene Mist
R-(-)-Epinephrine
R-Adrenaline
RCRA waste no. P042
Racemic Epinephrine
Racepinephrine
Rcra waste number P042
Renagladin
Renaglandin
Renaglandulin
Renaleptine
Renalina
Renoform
Renostypricin
Renostypticin
Renostyptin
SMP1_000227
ST069368
SUS-PHRINE SULFITE-FREE
Scurenaline
Septocaine
Simplene
Sindrenina
Soladren
Sphygmogenin
Stryptirenal
Styptirenal
Supracapsulin
Supradin
Supranefran
Supranephrane
Supranephrine
Supranol
Suprarenaline
Suprarenin
Suprel
Surenine
Surrenine
Sus-Phrine
Sus-phrine
Susphrine
Sympathin I
Takamina
Takamine
Tokamina
Tonogen
Twinject
Twinject 0.15
Twinject 0.3
Twinject 0.30
UNII-YKH834O4BH
Vaponefrin
Vasoconstrictine
Vasoconstrictor
Vasodrine
Vasoton
Vasotonin
adrenaline
bmse000316
d-Adrenaline
epinephrine
l-1-(3,4-Dihydroxyphenyl)-2-methylaminoethanol
l-Adrenalin
l-Adrenaline
l-Epinephine
l-Epinephrine (synthetic)
l-Epirenamine
l-Methylaminoethanolcatechol
levoepinephrine
nchembio747-comp9
3
Glycerolexperimental, approvedPhase 422356-81-5753
Synonyms:
1,2,3-Trihydroxypropane
1,2,3-propanetriol
1,2,3-trihydroxypropane
Bulbold
Cristal
E 422
Emery 916
Glyceol Opthalgan
Glycerin
Glycerin, anhydrous
Glycerin,anhydrous
Glycerine
Glycerinum
 
Glyceritol
Glycerol
Glycyl alcohol
Glyrol
Glysanin
IFP
Incorporation factor
Mackstat H 66
Monoctanoin component D
Osmoglyn
Pricerine 9091
Propanetriol
RG-S
Trihydroxypropane
Tryhydroxypropane
4AnestheticsPhase 4, Phase 39001
5RacepinephrinePhase 4, Phase 3933
6Epinephryl boratePhase 4, Phase 3933
7Central Nervous System DepressantsPhase 4, Phase 312806
8
HistamineapprovedPhase 3103475614-87-8, 51-45-6774
Synonyms:
.beta.-Imidazolyl-4-ethylamine
1H-Imidazole-4-ethanamine
1H-Imidazole-5-ethanamine
1avn
1qft
2-(1H-Imidazol-4-yl)ethanamine
2-(1H-Imidazol-4-yl)ethylamine
2-(1H-Imidazol-5-yl)ethanamine
2-(1H-Imidazol-5-yl)ethylamine
2-(1H-imidazol-4-yl)ethan-1-amine
2-(1H-imidazol-5-yl)ethanamine
2-(3H-Imidazol-4-yl)-ethylamine
2-(4-Imidazolyl)ethanamine
2-(4-Imidazolyl)ethylamine
2-Imidazol-4-yl-Ethylamine
2-Imidazol-4-ylethylamine
2-[4-Imidazolyl]ethylamine
4-(2-Aminoethyl)-1H-imidazole
4-(2-Aminoethyl)imidazole
4-Imidazoleethylamine
5-Imidazoleethylamine
51-45-6
53290_FLUKA
64422-25-9
924364-91-0
AC-13185
AC1L19ZT
AC1Q54BV
AC1Q54BW
AKOS000274386
ALBB-005968
BCBcMAP01_000250
BSPBio_001117
BSPBio_002124
Bio1_000487
Bio1_000976
Bio1_001465
Bio2_000389
Bio2_000869
C00388
CCRIS 6535
CHEBI:18295
CHEMBL90
CID774
D08040
DivK1c_000308
EINECS 200-100-6
Eramin
Ergamine
Ergotidine
F411C768-A159-4FC0-A195-291A08BB03AA
Free histamine
H7125_SIGMA
HMS1362G19
HMS1792G19
HMS1990G19
HSDB 3338
HSM
Histamine
Histamine (DCF)
Histamine Base
Histamine [USAN]
Histamine, Free Base
Histaminum
 
Histaminum (TN)
IDI1_000308
IDI1_002144
Imidazole-4-ethylamine
Istamina
Istamina [Italian]
KBio1_000308
KBio2_000457
KBio2_001325
KBio2_003025
KBio2_003893
KBio2_005593
KBio2_006461
KBio3_000853
KBio3_000854
KBio3_001344
KBioGR_000457
KBioGR_001580
KBioSS_000457
KBioSS_001325
L-Histamin base
L-Histamine
L-histamine
L000292
LS-75835
Lopac-H-7250
Lopac0_000595
MLS000069447
MolPort-001-785-597
MolPort-002-042-264
NCGC00015513-01
NCGC00015513-08
NCGC00093371-02
NCGC00093371-03
NCGC00093371-04
NCGC00093371-05
NINDS_000308
NSC 33792
NSC33792
SDCCGMLS-0066601.P001
SMP1_000151
SMR000059091
SPBio_000729
ST073926
STK346752
STOCK5S-55669
Spectrum2_000665
Spectrum3_000452
Spectrum4_000960
Spectrum5_000796
Spectrum_000845
Theramine
UNII-820484N8I3
WLN: T5M CNJ D2Z
ZERO/004089
[3H]histamine
b-Imidazolyl-4-ethylamine
beta-Aminoethylglyoxaline
beta-Aminoethylimidazole
beta-Aminothethylglyoxaline
beta-Imidazolyl-4-ethylamine
beta-aminothethylglyoxaline
bmse000744
histamine
nchembio.87-comp54
nchembio714-comp1
9
LoratadineapprovedPhase 39979794-75-53957
Synonyms:
1-Piperidenecarboxylic acid, 4-(8-chloro-5,6-duhydro-11H-benzo [5,6]cyclohepta[1,2-b]-pyridin-11-ylidene)-, ethyl ester
1-Piperidinecarboxylic acid, 4-(8-chloro-5,6-dihydro-11H-benzo(5,6)cyclohepta(1,2-b)pyridin-11-ylidene)-, ethyl ester
1-Piperidinecarboxylic acid, 4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)-, ethyl ester
1-piperidinecarboxylic acid,4-(8-chloro-5,6-dihydro-11H-benzo(5,6)cyclohepta(1,2-b)pyridin-11-ylidene)-,ethyl ester
4-(8-Chloro-5,6-dihydro-11H-benzo(5,6)cyclohepta(1,2-b)pyridin-11-ylidene)-1-piperidinecarboxylic Acid Ethyl Ester
4-(8-Chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene-1-piperidinecarboxylic acid ethyl ester
4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cycloheptal[1,2-b]pyridin-11-ylidene-1-piperidinecarboxylic acid ethyl ester
79794-75-5
AC-2086
AC1L1H3E
Aerotina
Alarin
Alavert
Alavert, Claritin, Loratadine
Alerpriv
Allertidin
Amantadine
Anhissen
BB_SC-2109
BIDD:GT0198
BRD-K82795137-001-02-3
BRD-K82795137-001-10-6
BSPBio_002300
Bedix Loratadina
Biloina
Bonalerg
C22H23ClN2O2
CHEMBL998
CID3957
CPD000058255
Children's Claritin
Civeran
Claratyne
Claratyne Cold
Claratyne Decongestant
Clarinase
Clarinase Reperabs
Claritin
Claritin (TN)
Claritin D
Claritin Hives Relief
Claritin Hives Relief Reditab
Claritin Reditabs
Claritin reditab
Claritine
Clarityn
Clarityne
Clarityne Dy Repetabs
Clarityne-D
Clarium
Cronopen
D00364
D017336
DB00455
DivK1c_000792
EU-0100680
Ethyl 4-(8-chloro-5,6-dihydro-11H-benzo(5,6)cyclohepta(1,2-b)pyridin-11-ylidene)-1-piperidinecarboxylate
Flonidan
Fristamin
HMS2051G11
HMS2090O18
HMS2093I15
HMS502H14
HSDB 3578
Histaloran
I14-0747
IDI1_000792
KBio1_000792
KBio2_001976
KBio2_004544
KBio2_007112
KBio3_001520
KBioGR_000693
KBioSS_001976
Klaritin
L 9664
L000667
L0223
L9664_SIGMA
LS-114660
 
Lergy
Lertamine
Lesidas
Lisino
Lopac-L-9664
Lopac0_000680
Loracert
Loradex
Loradif
Loranox
Lorantis
Lorastine
Loratadina
Loratadina [Spanish]
Loratadine
Loratadine (JAN/USAN/INN)
Loratadine Redidose
Loratadine Wyeth Brand
Loratadine [USAN:BAN:INN]
Loratadinum
Loratadinum [Latin]
Loratidine
Loratyne
Loraver
Lorfast
Loritine
Lowadina
MLS000069647
MLS000758260
MLS001148466
MolPort-002-507-846
NCGC00015619-01
NCGC00015619-02
NCGC00015619-06
NCGC00015619-10
NCGC00023125-02
NCGC00023125-04
NCGC00023125-05
NCGC00023125-06
NCGC00023125-07
NCI60_041473
NINDS_000792
NSC721075
Nularef
Oprea1_027965
Optimin
Polaratyne
Pylor
Restamine
Rhinase
Rinomex
Roletra
S1358_Selleck
SAM001246987
SMR000058255
SPBio_001548
SPECTRUM1503712
STK574925
Sanelor
Sch 29851
Sch-29851
Sch29851
Sensibit
Sinhistan Dy
Sohotin
Spectrum2_001584
Spectrum3_000740
Spectrum4_000177
Spectrum5_001650
Spectrum_001496
TL8005389
Tadine
Talorat Dy
Tocris-1944
UNII-7AJO3BO7QN
Velodan
Versal
Wyeth Brand of Loratadine
ZINC00537931
Zeos
ethyl 4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)piperidine-1-carboxylate
loratadine
10
Histamine PhosphateapprovedPhase 3103351-74-165513
Synonyms:
1H-Imidazole-4-ethanamine, phosphate (1:2)
2-Imidazol-4-ylethylamine orthophosphoric acid (1:2)
4-(2-Aminoethyl)imidazole bis(dihydrogen phosphate)
4-(2-Aminoethyl)imidazole di-acid phosphate
4-2(2-Aminoethyl)Imidazole-Di-Acid Phosphate
51-74-1
53623-99-7
74-56-6
AC1L23E4
CID65513
D04445
DB00667
 
EINECS 200-118-4
H0147
Histamine acid phosphate
Histamine biphosphate
Histamine dihydrogen phosphate
Histamine diphosphate
Histamine phosphate (1:2)
Histamine phosphate (TN)
Histamine phosphate (USP)
Histamine phosphate [USP]
Histamine positive
Histaminum
LS-78569
UNII-QWB37T4WZZ
11
deoxycholic acidapprovedPhase 3, Phase 1, Phase 24083-44-3222528
Synonyms:
(3α,5β,12α)-3,12-dihydroxycholan-24-oic acid
3alpha,12alpha-Dihydroxy-5beta-cholanic acid
5b-Cholanic acid-3a,12a-diol
5b-Deoxycholate
5b-Deoxycholic acid
7-Deoxycholate
7-Deoxycholic acid
7α-deoxycholic acid
Cholerebic
 
Cholorebic
Degalol
Deoxy-Cholate
Deoxy-Cholic acid
Deoxycholatate
Deoxycholate
Deoxycholatic acid
Deoxycholic acid
Desoxycholsäure
deoxycholate
desoxycholic acid
12
IbuprofenapprovedPhase 350115687-27-13672
Synonyms:
(+-)-2-(P-Isobutylphenyl)propionic acid
(+-)-Ibuprofen
(+-)-P-Isobutylhydratropic acid
(+-)-alpha-Methyl-4-(2-methylpropyl)benzeneacetic acid
(4-Isobutylphenyl)-alpha-methylacetic acid
(RS)-ibuprofen
139466-08-3
15687-27-1
2-(4-Isobutylphenyl)propanoic acid
4-Isobutylhydratropic acid
58560-75-1
AC-11312
AC1L1GGE
AC1Q1P84
AC1Q1P85
ACHES-N-PAIN
ARONIS23835
Act-3
Actiprofen
Adex 200
Adran
Advil
Advil (TN)
Advil Liqui-Gels
Ak+C2278tren
Alaxan
Algofen
Am-Fam 400
Amelior
Amersol
Amibufen
Anafen
Anco
Andran
Anflagen
Antagil
Antalfene
Antarene
Antiflam
Apo-Ibuprofen
Apsifen
Apsifen-F
Artofen
Artril
Artril 300
BB_SC-1358
BIDD:GT0050
BRN 2049713
Balkaprofen
Betaprofen
Bloom
Bluton
Brofen
Brufanic
Brufen
Brufen 400
Bruflam
Brufort
Buburone
Bufeno
Bufigen
Bukrefen
Bupron
Buracaps
Burana
Butylenin
C01588
C13H18O2
CCRIS 3223
CHEBI:5855
CHEMBL521
CID3672
CPD000058184
Cap-Profen
Carol
Cesra
Children's Advil
Children's Elixsure
Children's Ibuprofen
Children's Motrin
Citalgan
Cobo
Codral
Combiflam
Cunil
D00126
D007052
DB01050
DOLO PUREN
Daiprophen
Dalsy
Dansida
Deep Relief
Dentigoa
Dibufen
Dignoflex
Dolgin
Dolgirid
Dolgit
Dolibu
Dolmaral
Dolo-Dolgit
Dolo-dolgit
Dolocyl
Dolofen
Dolofen-F
Dolofin
Dolofort
Dologel
Dolomax
Doloren
Dolormin
Doltibil
Dolven
Donjust B
Dorival
Drin
Duafen
Duobrus
Dura-Ibu
Duralbuprofen
Dysdolen
EU-0100691
Easifon
Ebufac
Emflam
Emflam-200
Emodin
Epobron
Eputex
Ergix
Esprenit
Exneural
Faspic
Femadon
Femafen
Femapirin
Femidol
Fenbid
Fenbid Spansule
Fendol
Fenspan
Fibraflex
Gelufene
Gofen
Grefen
Gynofug
HMS1920F15
HMS2089P05
HMS2091N03
HMS502M09
HSDB 3099
Haltran
I 4883
I01-7039
I0415
I4883_SIGMA
I7905_SIAL
IB-100
IDI1_000887
IP 82
IP-82
IP82
Ibol
Ibren
Ibu
Ibu-Attritin
Ibu-Slo
Ibu-Tab
Ibu-Tab 200
Ibu-attritin
Ibu-slo
Ibu-slow
Ibubest
Ibubeta
Ibucasen
Ibudol
 
Ibudolor
Ibufen
Ibuflamar
Ibufug
Ibugel
Ibugen
Ibugesic
Ibuhexal
Ibulagic
Ibular
Ibulav
Ibuleve
Ibulgan
Ibumed
Ibumerck
Ibumetin
Ibupirac
Ibuprin
Ibuprocin
Ibuprofen
Ibuprofene
Ibuprofeno
Ibuprofenum
Ibuprohm
Ibuprophen
Ibusal
Ibutid
Ifen
Inabrin
Inflam
Inoven
Ipren
Irfen
Isodol
Jenaprofen
Junifen
Junior Strength Advil
Junior Strength Ibuprofen
Junior Strength Motrin
KBio1_000887
KBio2_001329
KBio2_003897
KBio2_006465
KBio3_001390
Kesan
Kratalgin
LS-7454
Lamidon
Lebrufen
Librofem
Lidifen
Liptan
Lopane
MLS000069733
MLS001146965
Malafene
Manypren
Medipren
Melfen
Mensoton
Midol
Midol 200
Moment
Motrin
Motrin (TN)
Motrin IB
Mynosedin
NCI60_002065
NINDS_000887
NSC 256857
NSC256857
Nagifen-D
Napacetin
Narfen
Neo-Helvagit
Neo-Mindol
NeoProfen
Neobrufen
Nerofen
Noalgil
Nobafon
Nobfelon
Nobfen
Nobgen
Noritis
Norton
Novadol
Novo-Profen
Novogent
Novogent N
Novoprofen
Nuprilan
Nuprin
Nurofen
Optifen
Opturem
Oralfene
Ostarin
Ostofen
Ozonol
P-Isobutylhydratropic Acid
Paduden
Panafen
Pantrop
Para-Isobutylhydratropic Acid
Paxofen
Pedia-Profen
PediaProfen
Pediaprofen
Pediatric Advil
Perofen
Proartinal
Profen
Proflex
Provon
Quadrax
R.D. 13621
RD 13621
Rafen
Ranofen
Rebugen
Relcofen
Rhinadvil
Rofen
Roidenin
Rufen
Rufin
Rupan
SAM002264619
SMR000058184
SPBio_000178
STK177358
Sadefen
Salivia
Salprofen
Seclodin
Sednafen
Seklodin
Seskafen
Siyafen
Solpaflex
Solufen
Stelar
Sugafen
Suprafen
Suspren
Syntofene
TL8001184
Tab-Profen
Tabalon
Tabalon 400
Tatanal
Tempil
Tofen
Togal N
Tonal
Trendar
U 18573
U-18,573
U-18573
UCB 79171
Unipron
Upfen
Uprofen
Urem
VUFB 9649
Zafen
Zofen
alpha-(4-Isobutylphenyl)propionate
alpha-(4-Isobutylphenyl)propionic acid
alpha-(P-Isobutylphenyl)propionic acid
alpha-p-Isobutylphenylpropionate
alpha-p-Isobutylphenylpropionic acid
ibuprofen
p-Isobutyl-2-phenylpropionate
p-Isobutyl-2-phenylpropionic acid
p-Isobutylhydratropate
p-Isobutylhydratropic acid
13
CopperapprovedPhase 317215158-11-9, 7440-50-827099
Synonyms:
 
Copper
Cu
14Dermatologic AgentsPhase 35674
15Histamine H1 AntagonistsPhase 3782
16Diuretics, Potassium SparingPhase 31827
17Gastrointestinal AgentsPhase 3, Phase 1, Phase 28109
18Histamine AntagonistsPhase 3946
19Peripheral Nervous System AgentsPhase 322776
20Sodium Channel BlockersPhase 31515
21Vasoconstrictor AgentsPhase 32027
22Respiratory System AgentsPhase 34818
23Pharmaceutical SolutionsPhase 3, Phase 2, Early Phase 17793
24Neurotransmitter AgentsPhase 317734
25Histamine H1 Antagonists, Non-SedatingPhase 3354
26MydriaticsPhase 3763
27Analgesics, Non-NarcoticPhase 36260
28Anesthetics, LocalPhase 33272
29Anti-Allergic AgentsPhase 31490
30AnalgesicsPhase 311287
31Adrenergic beta-AgonistsPhase 31640
32Cyclooxygenase InhibitorsPhase 32778
33Adrenergic AgonistsPhase 32877
34Adrenergic alpha-AgonistsPhase 31625
35Anti-Arrhythmia AgentsPhase 32969
36Adrenergic AgentsPhase 35140
37Autonomic AgentsPhase 39774
38Anti-Asthmatic AgentsPhase 33369
39Cholagogues and CholereticsPhase 3, Phase 1, Phase 2127
40Antirheumatic AgentsPhase 310627
41Bronchodilator AgentsPhase 32856
42Anti-Inflammatory Agents, Non-SteroidalPhase 34295
43Anti-Inflammatory AgentsPhase 310355
44AntipruriticsPhase 3864
45Trace ElementsPhase 35802
46MicronutrientsPhase 35802
47histidineNutraceuticalPhase 342
48
Hydrocodoneapproved, illicit119125-29-15284569
Synonyms:
(-)-Dihydrocodeinone
(5alpha)-17-methyl-3-(methyloxy)-4,5-epoxymorphinan-6-one
1037-91-8
125-29-1
3-methoxy-17-methyl-4,5alpha-epoxymorphinan-6-one
34195-34-1 (tartrate (1:1), hydrate (2:5))
4,5-alpha-Epoxy-3-methoxy-17-methylmorphinan-6-one
4,5.alpha.-Epoxy-3-methoxy-17-methylmorphinan-6-one
4,5alpha-Epoxy-3-methoxy-17-methylmorphinan-6-one
4-27-00-03580 (Beilstein Handbook Reference)
50678-79-0
6-Oxo-3-methoxy-N-methyl-4,5-epoxymorphinan
9007-52-7
BRN 0094193
Bekadid
C08024
CHEBI:5779
CHEMBL1457
CID5284569
Codinovo
D08045
DB00956
DEA No. 9193
DICO
Dico
Dicodid
Dihydrocodeinone
EINECS 204-733-9
 
HSDB 3097
HYDROCODONE
Hidrocodona
Hidrocodona [INN-Spanish]
Hydrocodeinonebitartrate
Hydrocodon
Hydrocodone
Hydrocodone (INN)
Hydrocodone [INN:BAN]
Hydrocodonum
Hydrocodonum [INN-Latin]
Hydrocon
Hydrocone
Hydroconum
Idrocodone
Idrocodone [DCIT]
Idrocodone [Dcit]
LS-92156
MolPort-002-527-170
Morphinan-6-one, 4,5-epoxy-3-methoxy-17-methyl-, (5alpha)- (9CI)
Morphinan-6-one, 4,5alpha-epoxy-3-methoxy-17-methyl- (8CI)
Multacodin
NCGC00159317-02
NCGC00159317-03
NSC 19044
NSC19044
STOCK1N-54181
UNII-6YKS4Y3WQ7
WLN: T B6566 B6/CO 4ABBC R BX FV HO PN GHT&&TTJ JO1 P1
hidrocodona
49
Hyaluronic acidapproved, vet_approved4399004-61-953477741, 24759
Synonyms:
Hyaluronan
Hyaluronate
Hyaluronic acid
Hylartil
Hyruan Plus
Luronit
 
Macronan
Mucoitin
Nutra-HAF
Q 5AQ
Sepracoat
Sepragel Sinus
Sofast
Synvisc
50
Acetylcholineapproved77651-84-3187
Synonyms:
ACh
Acetyl choline ion
Acetylcholine Chloride
Acetylcholine cation
 
Acetylcholinium: acetyl-Choline
Choline acetate
Choline acetate (ester)
O-Acetylcholine
acetylcholine chloride

Interventional clinical trials:

(show top 50)    (show all 61)
idNameStatusNCT IDPhase
1Suture Granuloma in Body Contouring SurgeryCompletedNCT00223132Phase 4
2Vibration-Assisted AnaesthesiaCompletedNCT00793988Phase 4
3Change in Skin Elasticity With RF and PEMFRecruitingNCT03002194Phase 4
4Patient Experience Study of Deoxycholic Acid InjectionCompletedNCT02007434Phase 3
5Safety Study of ATX-101 in Subjects With Varying Chin SizesCompletedNCT02035267Phase 3
6Open-Label Study of Deoxycholic Acid for the Reduction of Localized Subcutaneous Fat in the Submental AreaCompletedNCT01426373Phase 3
7Molecular Bases of Response to Copper Treatment in Menkes Disease, Related Phenotypes, and Unexplained Copper DeficiencyRecruitingNCT00811785Phase 3
8Phase 1-2 Study of Deoxycholic Acid Injection (ATX-101) for the Reduction of Submental FatCompletedNCT00618722Phase 1, Phase 2
9Phase 2 Study of XAF5 (XOPH5) Ointment for Reduction of Excess Eyelid Fat (Steatoblepharon)CompletedNCT02230761Phase 2
10Phase 2 Study of Deoxycholic Acid Injection (ATX-101) for the Reduction of Submental FatCompletedNCT00618618Phase 2
11Efficacy Study for Magnetic Induction to Treat WrinklesUnknown statusNCT01701440
12Levator Muscle Strength EvaluationUnknown statusNCT02226016
13Feasibility Study: Evaluation of the Ulthera® System for Treatment of the KneesCompletedNCT01708434
14Evaluation of the Ulthera™ System for Obtaining Lift and Tightening of the Cheek TissueCompletedNCT01368835
15Feasibility Study: Higher Density Ulthera® System Treatment With Vectoring for Treatment of the Face and NeckCompletedNCT01708512
16Lifting and Tightening of the Face in Subjects With Skin of Darker ColorCompletedNCT01368965
17Ultherapy™ Treatment Following Sculptra® TreatmentCompletedNCT01422538
18Feasibility Study: Lifting and Tightening of the ElbowsCompletedNCT01708382
19Lifting and Tightening of the Face and Neck Following an Increased Density TreatmentCompletedNCT01519206
20Feasibility Study: Compare the Effectiveness Between Two Pain Medications When Used Prior to Ultherapy™ TreatmentsCompletedNCT01708473
21Application of the Apsara Thermal Wand SystemCompletedNCT00662389Early Phase 1
22Feasibility Study: Evaluate the Effectiveness of Using a Topical Anesthetic Prior to Ultherapy™ TreatmentCompletedNCT01708447
23Treatment of the Face and Neck With Lower Ulthera System Energy SettingsCompletedNCT01713998
24Feasibility Study: Treatment of Post-surgery and Surgery Naive Patients Who Failed to Respond to a Previous Ulthera TreatmentCompletedNCT01708252
25Feasibility Study: Evaluation of the Ulthera® System for Treatment of the DécolletéCompletedNCT01485107
26Feasibility Study: Lifting and Tightening Neck Skin in PatientsCompletedNCT01708928
27Feasibility Study: Heavy Water Tissue Labeling ProtocolCompletedNCT01708525
28Feasibility Study: Ulthera Treatment of the Buttocks and ThighsCompletedNCT01708460
29Ultherapy® for Treating the Face and Neck Using Standard Versus Simulines TransducersCompletedNCT02416076
30Retrospective Evaluation of Combination Treatment With the Ulthera SystemCompletedNCT02444169
31Efficacy of Long Pulsed 1064nm Laser for Facial Skin TighteningCompletedNCT01971736
32Lifting and Tightening of the Face and Neck Utilizing the Ulthera® SystemCompletedNCT01368874
33Evaluation of CoolSculpt Combining Venus Legacy Technology for Enhanced Results in Fat Reduction and Laxity of the FlanksCompletedNCT02569112
34Feasibility Study: Evaluation of Ulthera Versus Thermage for Treating the Face and NeckCompletedNCT01713985
35Feasibility Study: Evaluation of the Ulthera® System for Treatment of Abdominal TissueCompletedNCT01708499
36A Retrospective Study to Evaluate the Effectiveness of the Ulthera SystemCompletedNCT01519934
37Use of 2-octyl-cyanoacrylate Together With a Self-adhering MeshCompletedNCT01658163
38Evaluation of the Ulthera® System for Treatment of the BrachiaCompletedNCT01713933
39Silk'n HST for Wrinkle Reduction - Clinical Study ProtocolCompletedNCT02913547
40Clinical Trial to Evaluate Safety and Efficacy of Ultherapy™ System for Lifting Skin on the NeckCompletedNCT02368925
41Evaluation of Safety and Efficacy of Using Imagine™ Computerized Radiofrequency System for Skin TighteningCompletedNCT00945685
42Evaluation of Safety and Efficacy of Using EndyMed Pro Skin Treatment System for Skin Wrinkle Treatment on Body AreasCompletedNCT01029301
43Comparison of the Effects of Carboxytherapy and Radiofrequency on Skin RejuvenationCompletedNCT01981980
44Thermage CPT for Treatment of Facial and Neck LaxityCompletedNCT01783496
45Safety and Efficacy Evaluation of Ultherapy™ System in Aging HandCompletedNCT02364440
46Body Contouring Surgery After Massive Weight LossCompletedNCT02174458
47Condition of Submental Fullness and Treatment Outcomes RegistryCompletedNCT02438813
48Topical Bimatoprost for Chemical BlepharoplastyRecruitingNCT02830776Early Phase 1
49Safety and Effectiveness Evaluation of the Device in Achieving Submental LiftRecruitingNCT02832674
50Gene Expression Following Ultherapy® TreatmentRecruitingNCT02441036

Search NIH Clinical Center for Cutis Laxa


Cochrane evidence based reviews: cutis laxa

Genetic Tests for Cutis Laxa

About this section

Genetic tests related to Cutis Laxa:

id Genetic test Affiliating Genes
1 Cutis Laxa27

Anatomical Context for Cutis Laxa

About this section

MalaCards organs/tissues related to Cutis Laxa:

36
Skin, Heart, Lung, Bone, Tongue, Eye, Brain

Publications for Cutis Laxa

About this section

Articles related to Cutis Laxa:

(show top 50)    (show all 356)
idTitleAuthorsYear
1
Mutations in ATP6V1E1 or ATP6V1A Cause Autosomal-Recessive Cutis Laxa. (28065471)
2016
2
Cutis laxa acquisita: novel insights into impaired elastic fibre regeneration. (27873303)
2016
3
A de novo 1q23.3-q24.2 deletion combined with a GORAB missense mutation causes a distinctive phenotype with cutis laxa. (27604556)
2016
4
Cutis laxa autosomal recessive type II or wrinkly skin syndrome? (27730053)
2016
5
ALDH18A1-related cutis laxa syndrome with cyclic vomiting. (26829900)
2016
6
Penicillamine-associated cutis laxa and milia en plaque - case report and review of cutaneous changes associated with penicillamine. (27617526)
2016
7
Generalized acquired cutis laxa type 1: a case report and brief review of literature. (27136630)
2016
8
Acquired Localized Cutis Laxa due to Increased Elastin Turnover. (27293393)
2016
9
A 5-year Journey with Cutis Laxa in an Indian Child: The De Barsy Syndrome Revisited. (26955101)
2016
10
Functional consequence of fibulin-4 missense mutations associated with vascular and skeletal abnormalities and cutis laxa. (27339457)
2016
11
Neonatal Cutis Laxa and Hypertrichosis Lanuginosa in Sotos Syndrome. (27601358)
2016
12
Frequency of cutis laxa-like clinical features and elastolysis in scleromyxedema: a retrospective clinicopathologic study of 19 patients with scleromyxedema. (26676919)
2016
13
Polymicrogyria and myoclonic epilepsy in autosomal recessive cutis laxa type 2A. (27631729)
2016
14
Acquired cutis laxa associated with cutaneous mastocytosis. (26436968)
2015
15
Fractional photothermolysis treatment of digital cutis laxa reverses hand disability. (25808794)
2015
16
Acral localized acquired cutis laxa: report of a case associated with inflammatory arthritis. (25497952)
2015
17
The Diagnostic Dilemma of Cutis Laxa: A Report of Two Cases with Genotypic Dissimilarity. (26538727)
2015
18
Clinical presentation of a patient with cutis laxa with systemic involvement: a case report. (26662161)
2015
19
Congenital Cutis Laxa Type 2 Associated With Recurrent Aspiration Pneumonia and Growth Delay: Case Report. (26516448)
2015
20
Autosomal-dominant cutis laxa resulting from an intronic mutation in ELN. (26121527)
2015
21
Generalized acquired cutis laxa with papular lesions. (25516168)
2015
22
Developmental retardation in postinflammatory elastolysis and cutis laxa. (26345649)
2015
23
Acquired localized cutis laxa occurring on the face after delivery. (25652808)
2015
24
Cutis Laxa syndrome: a case report. (25995800)
2015
25
Fibulin-4 E57K Knock-in Mice Recapitulate Cutaneous, Vascular and Skeletal Defects of Recessive Cutis Laxa 1B with both Elastic Fiber and Collagen Fibril Abnormalities. (26178373)
2015
26
Modeling autosomal recessive cutis laxa type 1C (ARCL1C) in mice reveals distinct functions of Ltbp-4 isoforms. (25713297)
2015
27
Recurrent De Novo Mutations Affecting Residue Arg138 of Pyrroline-5-Carboxylate Synthase Cause a Progeroid Form of Autosomal-Dominant Cutis Laxa. (26320891)
2015
28
Trachyonychia, Cutis Laxa, and Easy Bruising of the Skin. (25322068)
2014
29
Baroreflex failure, sympathetic storm, and cerebral vasospasm in fibulin-4 cutis laxa. (24733866)
2014
30
Loss of ALDH18A1 function is associated with a cellular lipid droplet phenotype suggesting a link between autosomal recessive cutis laxa type 3A and Warburg Micro syndrome. (25077174)
2014
31
Acral Acquired Cutis Laxa Associated with IgA Multiple Myeloma, Joint Hyperlaxity and Urticarial Neutrophilic Dermatosis. (24676529)
2014
32
Cutis laxa with pulmonary emphysema, conjunctivochalasis, nasolacrimal duct obstruction, abnormal hair, and a novel FBLN5 mutation. (24962763)
2014
33
Acquired cutis laxa: diagnostic and therapeutic considerations. (25027942)
2014
34
Retinitis pigmentosa, cutis laxa, and pseudoxanthoma elasticum-like skin manifestations associated with GGCX mutations. (24739904)
2014
35
Clinical presentation of a patient with congenital cutis laxa and abnormal thyroid hormone levels. (24707249)
2014
36
Autosomal recessive cutis laxa type 2A (ARCL2A) mimicking Ehlers-Danlos syndrome by its dermatological manifestations: report of three affected patients. (24478233)
2014
37
A novel elastin gene mutation in a Vietnamese patient with cutis laxa. (24758204)
2014
38
Bilateral congenital entropion with cutis laxa. (24517732)
2014
39
Postoperative intussusception in a neonate with congenital cutis laxa and huge hiatal hernia. (24834384)
2014
40
Biomechanical properties of the skin in cutis laxa. (24844858)
2014
41
Severe congenital cutis laxa with cardiovascular manifestations due to homozygous deletions in ALDH18A1. (24913064)
2014
42
Acquired cutis laxa associated with heavy chain deposition disease involving dermal elastic fibers. (25133950)
2014
43
Cutis laxa, fat pads and retinopathy due to ALDH18A1 mutation and review of the literature. (24767728)
2014
44
Acquired cutis laxa of face with multiple myeloma. (25201849)
2014
45
Identification of two novel ATP6V0A2 mutations in an infant with cutis laxa by exome sequencing. (24815019)
2014
46
Cutis laxa presenting as recurrent ileus. (25008264)
2014
47
A novel phenotype associated with cutis laxa, abnormal fat distribution, cardiomyopathy and cataract. (24459010)
2014
48
Oculoplastic approach to congenital cutis laxa syndrome. (23443999)
2013
49
Radiologic findings in cutis laxa syndrome and unusual association with hypertrophic pyloric stenosis. (24046787)
2013
50
Primary systemic amyloidosis, acquired cutis laxa and cutaneous mucinosis in a patient with multiple myeloma. (24346874)
2013

Variations for Cutis Laxa

About this section

Expression for genes affiliated with Cutis Laxa

About this section
Search GEO for disease gene expression data for Cutis Laxa.

Pathways for genes affiliated with Cutis Laxa

About this section

GO Terms for genes affiliated with Cutis Laxa

About this section

Cellular components related to Cutis Laxa according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1elastic fiberGO:007195310.6ELN, FBLN5
2extracellular matrixGO:00310129.6FBLN5, FBN1, LTBP4
3extracellular regionGO:00055768.3EFEMP2, ELN, FBLN5, FBN1, LOX, LTBP4
4proteinaceous extracellular matrixGO:00055788.0ELN, FBLN5, FBN1, LOX, LTBP4

Biological processes related to Cutis Laxa according to GeneCards Suite gene sharing:

(show all 7)
idNameGO IDScoreTop Affiliating Genes
1cellular amino acid biosynthetic processGO:000865210.3ALDH18A1, PYCR1
2elastic fiber assemblyGO:004825110.3FBLN5, LOX
3L-proline biosynthetic processGO:005512910.2ALDH18A1, PYCR1
4proline biosynthetic processGO:000656110.2ALDH18A1, PYCR1
5extracellular matrix disassemblyGO:00226179.9ELN, FBN1
6regulation of cell growthGO:00015589.7FBLN5, LTBP4
7extracellular matrix organizationGO:00301989.0ELN, FBLN5, FBN1, LOX

Molecular functions related to Cutis Laxa according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1extracellular matrix structural constituentGO:00052019.5EFEMP2, ELN, FBN1
2calcium ion bindingGO:00055099.1EFEMP2, FBLN5, FBN1, LTBP4
3integrin bindingGO:00051788.8FBLN5, FBN1, LTBP4

Sources for Cutis Laxa

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet